Abstract

Ten of 23 patients with advanced measureable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin-C and 5-fluorouracil (SMF). The median duration of response is in excess of 7 months and responding patients have lived significantly longer than patients with progressive disease (7.5 + months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent axotemia in 9% of patients.

Keywords

MedicineNauseaMitomycin CGastroenterologyRegimenAzotemiaVomitingFluorouracilInternal medicineStreptozotocinProgressive diseaseSurgeryChemotherapyDiabetes mellitusEndocrinologyRenal function

Affiliated Institutions

Related Publications

Publication Info

Year
1978
Type
article
Volume
41
Issue
2
Pages
387-391
Citations
110
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

110
OpenAlex

Cite This

R. G. Wiggans, Paul V. Woolley, John S. Macdonald et al. (1978). Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer , 41 (2) , 387-391. https://doi.org/10.1002/1097-0142(197802)41:2<387::aid-cncr2820410201>3.0.co;2-x

Identifiers

DOI
10.1002/1097-0142(197802)41:2<387::aid-cncr2820410201>3.0.co;2-x